©WebNovelPub
Previous chapter:
Chapter 615 The Pharmaceutical Scheme Is On
Next chapter:
Chapter 617 The Original Capital Exit
PREVIEW
... trials with the U.S. Food and Drug Administration (FDA) at the same time. However, due to strict regulations and cautious approaches toward human trials in the United States, the application was denied. Consequently, Hans Biopharmaceutical shifted its focus entirely to Africa.
"Now that the results of Phase II trials are in and meet the required standards, the company is expected to reapply for Phase II trials in the U.S. If successful, the new drug for tuberculosis treatment will enter ...
YOU MAY ALSO LIKE